Adiponectin in Chronic Kidney Disease
Adiponectin in Chronic Kidney Disease
Adiponectin is the adipokine associated with insulin sensitization, reducing liver gluconeogenesis, and increasing fatty acid oxidation and glucose uptake. Adiponectin is present in the kidneys, mainly in the arterial endothelium and smooth muscle cells, as well as in the capillary endothelium, and might be considered as a marker of many negative factors in chronic kidney disease. The last few years have brought a rising body of evidence that adiponectin is a multipotential protein with anti-inflammatory, metabolic, anti-atherogenic, and reactive oxygen species (ROS) protective actions. Similarly, adiponectin has shown many positive and direct actions in kidney diseases, and among many kidney cells. Data from large cross-sectional and cohort studies showed a positive correlation between serum adiponectin and mortality in chronic kidney disease. This suggests a complex interaction between local adiponectin action, comorbidities, and uremic milieu. In this review we discuss the role of adiponectin in chronic kidney disease.
Read abstract on library site Access full article
Featured Learning Zones
You may be interested in...
The 2023 update of the German Society of Neurology’s guideline on Parkinson’s disease (PD) provides detailed recommendations on the use of transcranial brain parenchyma sonography (TCS) for early and differential diagnosis. This update addresses previously unspecified diagnostic criteria and investigator qualifications, offering a robust framework based on a systematic literature review.